Search
Filters
Clear All
  • 9
  • 39
  • 2
  • 561

Phase

  • 9
  • 8
  • 36
  • 8
  • 46
  • 6
  • 470
  • 553
  • 284

Found 611 in-health trials

A listing of in-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Pediatric Long-Term Follow-up and Rollover Study

M
Michael Ferguson, MD
1 years and older
All genders
Phase 4
Interventional
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenibd/or trametinib.
Learn More

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

G
Gregory Sokol, MD
20 years and younger
Healthy Volunteer
All genders
The study investigators are interested in learning more about how drugs, that are given tohildren by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of thisudy is to evaluate the …
Learn More

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

S
Sandeep Batra, MD
1-30 years
All genders
This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia that is likely to come back or spread.
Learn More

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

D
David Clark
18 years and older
Healthy Volunteer
All genders
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents thezed integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD2019 and beyond.
Learn More

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

S
Sherif Farag, MD
All genders
Observational
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
Learn More

A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

M
Mark Tann, MD
18-100 years
All genders
The primary question of interest is quantifying the relationship between Y-90 liver therapy and liver damage.
Learn More

A Pilot Study to assess Theragnostically Planned Liver Radiation with Functional DVH Analysis to Optimize Individualized Radiation Therapy

R
Ryan Rhome, MD
18-100 years
All genders
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer.
Learn More

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

T
Terry Vik, MD
18 years and younger
All genders
The purpose of this research study is to find out about the treatment effects of an antibody called murine 8H9 (mu8H9).
Learn More

A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative

J
Jodi Skiles
1-25 years
All genders
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT).
Learn More

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

K
Kathy Miller, MD
18 years and older
All genders
Phase 3
Interventional
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work inventing breast cancer from coming back (relapsing) in patients with high risk, HER2ve breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to ahemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it …
Learn More
601 - 610 of 611